MARKET

BCLI

BCLI

Brainstorm Cell Therapeutics I
OTCMQB
0.670
-0.027
-3.90%
Closed 15:47 05/11 EDT
OPEN
0.700
PREV CLOSE
0.697
HIGH
0.700
LOW
0.670
VOLUME
18.15K
TURNOVER
12.60K
52 WEEK HIGH
1.920
52 WEEK LOW
0.465
MARKET CAP
7.39M
P/E (TTM)
-0.6025
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCLI last week (0504-0508)?
Weekly Report · 23h ago
Weekly Report: what happened at BCLI last week (0427-0501)?
Weekly Report · 05/04 09:36
Weekly Report: what happened at BCLI last week (0420-0424)?
Weekly Report · 04/27 09:37
Weekly Report: what happened at BCLI last week (0413-0417)?
Weekly Report · 04/20 09:36
Weekly Report: what happened at BCLI last week (0406-0410)?
Weekly Report · 04/13 09:37
Weekly Report: what happened at BCLI last week (0330-0403)?
Weekly Report · 04/06 09:37
Brainstorm Cell Q4 EPS $(0.20) Beats $(0.37) Estimate
Benzinga · 03/31 22:49
BrainStorm Cell Therapeutics GAAP EPS of -$1.11 beats by $0.50
Seeking Alpha · 03/31 20:31
More
About BCLI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.

Webull offers Brainstorm Cell Therapeutics Inc stock information, including OTCMQB: BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.